ELDN - קפיטליזציית שוק eledon.com

Eledon Pharmaceuticals (ELDN) develops methods to protect transplanted organs by utilizing safe molecules to suppress the immune response. The current strategy relies on finding a major partner to bring its lead product to market, as there are no funds available for acquisitions. This chart illustrating the price evolution of the stock, where the market capitalization stands at 0.18, confirms the company's status as a developer of targeted antibodies to combat ALS and tissue rejection.

Eledon Pharmaceuticals (ELDN) is a specialized biotech asset with a limited scale of operations. The issuer's total market capitalization is calculated as the product of the current share price and the total number of outstanding shares. This indicator determines the market value of the business and its compliance with index criteria. The trend in the issuer's total market capitalization reflects market expectations regarding the success of the drug tegoprubart. A low capital base increases the potential for returns upon confirmation of the therapy's efficacy.